Physician profile
Gerald B Miley
NPI 1255385803
$56,997.00
in general payments reported to CMS, 2019-2025
18 companies · $304 in 2025
The $304 reported for 2025 was less than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $26K · 2020: $2,648 · 2021: $5,491 · 2022: $18K · 2023: $4,556 · 2024: $410 · 2025: $304.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $3,900 · Food and Beverage: $1,370.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $3,900.00 |
| Food and Beverage | $1,369.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $51,708.36 | 2019-2023 | |
| Novartis Pharmaceuticals Corporation | $1,325.62 | 2019-2025 | |
| Lilly USA, LLC | $580.06 | 2019-2021 | |
| Glaxosmithkline, LLC. | $491.69 | 2019-2020 | |
| Amgen INC. | $474.07 | 2019-2021 | |
| Ucb, INC. | $437.19 | 2023-2025 | Bimzelx, Cimzia |
| Astrazeneca Pharmaceuticals LP | $361.79 | 2019-2021 | |
| Celgene Corporation | $334.10 | 2019 | |
| Allergan, INC. | $261.17 | 2019-2020 | |
| Exactech, INC. | $177.00 | 2021 | |
| Davol INC. | $143.88 | 2024 | Arista Ah Flexitip |
| Janssen Pharmaceuticals, INC | $129.43 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $122.79 | 2021 | |
| Pfizer INC. | $113.74 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $107.93 | 2019 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $101.28 | 2019 | |
| Janssen Biotech, INC. | $86.95 | 2019 | |
| Genentech, INC. | $39.95 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gerald Miley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.